Skip to main content

Table 1 Subject demographics

From: Lung flute improves symptoms and health status in COPD with chronic bronchitis: A 26 week randomized controlled trial

Characteristic

Lung Flute (n = 33)

Control (n = 36)

p value

Age

68.88 Ā± 1.49

67.97 Ā± 1.29

0.58

Gender

Male = 29

Male = 32

0.89

Female = 4

Female = 4

Ā 

Race

Caucasian = 30

Caucasian = 33

0.91

African-American = 3

African-American = 3

Ā 

Smoking history ( pack yrs)

62.16 Ā± 7.13

60.26 Ā± 4.60

0.82

Smoking status

Current = 13

Current = 12

0.60

Ex = 20

Ex = 24

Ā 

FEV1 (liters)

1.71 Ā± 0.13

1.53 Ā± 0.11

0.30

FEV1% predicted

51.19 Ā± 2.98

49.13 Ā± 3.18

0.64

Baseline COPD medications N (%)

Ā Ā Ā 

- LAMA + LABA/ICS

11 (33.3)

19 (52.8)

0.31

- LABA/ICS

6 (18.2)

3 (8.3)

Ā 

- LAMA/LABA

2 (6.1)

1 (2.8)

Ā 

- LAMA

3 (9.0)

3 (8.3)

Ā 

- LABA

1 (3.0)

3 (8.3)

- SAMA/SABA

5 (15.2)

6 (16.7)

Ā 

- SABA/none

5 (15.2)

1 (2.8)

Ā 
  1. LAMA = long actiing anti-muscarinic agent (e.g. tiotropium), LABA = long acting Ī² agonist (e.g. formoterol), ICS = inhaled corticosteroid (e.g. budesonide), SAMA = short acting anti-muscarinic agent (e.g. ipratropium), SABA = short acting Ī² agonist (e.g. albuterol).